The company said it would start identifying a successor for Dolsten, a process which is expected to last several months.
Dolsten joined Pfizer as part of the Wyeth acquisition in 2009, when he was named president of Worldwide Research and Development with the responsibility to lead all of Pfizerβs research as well as development of all its treatments through mid-stage studies.
